Inverse-probability reweighting of NHANES 1988–1991 to 2021–2023 demographics projected 5.3 million US adults with ASCVD and ...

Despite guideline recommendations, evidence from randomized trials evaluating the appropriate low-density lipoprotein (LDL) cholesterol target for secondary prevention in patients with atherosclerotic ...

Target levels of LDL cholesterol keep going down, but should we use higher doses of statins to achieve those goals? Hydroxymethylglutaryl- coenzyme A (HMG-CoA) reductase inhibitors, otherwise known as ...

LDL cholesterol still drives treatment decisions in assessing heart disease risk, but a new study suggests apolipoprotein B (apoB), which measures artery-clogging particles, could do a better job. In ...

Incidence of primary end point lower for patients with target LDL level 55 mg/dL versus 70 mg/dL. (HealthDay News) — For patients with atherosclerotic cardiovascular disease (ASCVD), targeting a ...

MADRID, Spain—The European Society of Cardiology and the European Atherosclerosis Society (ESC/EAS) have updated their guidelines for the management of dyslipidemia, and while treatment goals have ...

As new scientifically grounded evidence is developed and validated, clinical, scientific, and policy experts representing key stakeholders gather every several years to review and revise the ...

Please provide your email address to receive an email when new articles are posted on . CETP inhibition may help high-risk patients reach their LDL goals and reduce risk for atherosclerotic CVD events ...

CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced the nomination of its lead in vivo development candidate, ...

For patients with atherosclerotic cardiovascular disease (ASCVD), targeting a low-density lipoprotein (LDL) cholesterol level of <55 mg/dL results in a lower risk for cardiovascular events, according ...